VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$2.50 USD
+0.03 (1.21%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.51 +0.01 (0.40%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.50 USD
+0.03 (1.21%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.51 +0.01 (0.40%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Zacks News
Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for VYNE Therapeutics Inc. (VYNE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Much Upside is Left in VYNE Therapeutics Inc. (VYNE)? Wall Street Analysts Think 626.2%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 626.2% in VYNE Therapeutics Inc. (VYNE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
OptiNose (OPTN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 118.18% and 14.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Can VYNE Therapeutics Inc. (VYNE) Climb 415.04% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for VYNE Therapeutics Inc. (VYNE) points to a 415% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
VYNE Gains on Preclinical Data for IPF Candidate
by Zacks Equity Research
VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0% and 67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About VYNE Therapeutics Inc. (VYNE) Rating Upgrade to Buy
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 13.33% and 58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 17.65% and 7.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About VYNE Therapeutics (VYNE) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to for VYNE Therapeutics (VYNE) stock based on the movements in the options market lately.
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of -5.88% and -12.51%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0.00% and -31.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 7.50% and -18.85%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 14.00% and -12.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?